Symbols / ABT $110.16 -0.07%
ABT Chart
About
Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company offers generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, hypertriglyceridemia, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. It also provides laboratory and transfusion medicine systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion serology testing; molecular diagnostics polymerase chain reaction instrument systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, and detect and measure infectious agents; point of care systems; cartridges for testing blood gas, chemistry, electrolytes, coagulation, and immunoassay; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; and drug and alcohol test. In addition, the company offers pediatric and adult nutritional products and infant formula; rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; diabetes care products, such as glucose and blood glucose monitoring systems; and neuromodulation devices for the management of chronic pain and movement disorders. Abbott Laboratories was founded in 1888 and is based in Abbott Park, Illinois.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Medical Devices | Market Cap | 191.42B |
| Enterprise Value | 197.42B | Income | 6.50B | Sales | 44.33B |
| Book/sh | 30.02 | Cash/sh | 5.14 | Dividend Yield | 229.00% |
| Payout | 63.44% | Employees | 115000 | IPO | — |
| P/E | 29.61 | Forward P/E | 17.65 | PEG | — |
| P/S | 4.32 | P/B | 3.67 | P/C | — |
| EV/EBITDA | 16.41 | EV/Sales | 4.45 | Quick Ratio | 1.02 |
| Current Ratio | 1.58 | Debt/Eq | 26.79 | LT Debt/Eq | — |
| EPS (ttm) | 3.72 | EPS next Y | 6.24 | EPS Growth | -80.90% |
| Revenue Growth | 4.40% | Earnings | 2026-04-15 | ROA | 6.63% |
| ROE | 12.96% | ROIC | — | Gross Margin | 56.66% |
| Oper. Margin | 21.62% | Profit Margin | 14.72% | Shs Outstand | 1.74B |
| Shs Float | 1.73B | Short Float | 1.05% | Short Ratio | 1.66 |
| Short Interest | — | 52W High | 139.06 | 52W Low | 105.27 |
| Beta | 0.74 | Avg Volume | 9.60M | Volume | 195.71K |
| Target Price | $133.17 | Recom | Buy | Prev Close | $110.24 |
| Price | $110.16 | Change | -0.07% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$133.17
Mean price target
2. Current target
$110.13
Latest analyst target
3. DCF / Fair value
$65.15
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$110.13
Low
$113.00
High
$158.00
Mean
$133.17
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2026-03-11 | main | Citigroup | Buy → Buy | $136 |
| 2026-02-02 | main | Barclays | Overweight → Overweight | $142 |
| 2026-01-23 | main | Citigroup | Buy → Buy | $140 |
| 2026-01-23 | main | Bernstein | Outperform → Outperform | $125 |
| 2026-01-23 | main | RBC Capital | Outperform → Outperform | $135 |
| 2026-01-23 | main | Oppenheimer | Outperform → Outperform | $132 |
| 2026-01-23 | main | Evercore ISI Group | Outperform → Outperform | $138 |
| 2026-01-23 | main | Piper Sandler | Overweight → Overweight | $135 |
| 2026-01-23 | main | BTIG | Buy → Buy | $140 |
| 2026-01-09 | main | Bernstein | Outperform → Outperform | $154 |
| 2026-01-05 | main | Barclays | Overweight → Overweight | $169 |
| 2025-11-20 | reit | BTIG | Buy → Buy | $145 |
| 2025-10-17 | main | Barclays | Overweight → Overweight | $162 |
| 2025-10-16 | main | Raymond James | Outperform → Outperform | $146 |
| 2025-10-16 | main | Evercore ISI Group | Outperform → Outperform | $142 |
| 2025-10-16 | reit | RBC Capital | Outperform → Outperform | $147 |
| 2025-10-16 | main | Wells Fargo | Overweight → Overweight | $146 |
| 2025-10-15 | reit | BTIG | Buy → Buy | $145 |
| 2025-10-10 | init | Benchmark | — → Buy | $145 |
| 2025-10-07 | main | Evercore ISI Group | Outperform → Outperform | $144 |
News
RSS: Latest ABT news- Q4 Earnings Highs And Lows: Abbott Laboratories (NYSE:ABT) Vs The Rest Of The Medical Devices & Supplies - Diversified Stocks - StockStory hu, 12 Mar 2026 09
- Abbott’s Freedom To Work Plan And What It May Mean For NYSE ABT - simplywall.st hu, 12 Mar 2026 09
- Citigroup Has Lowered Expectations for Abbott Laboratories (NYSE:ABT) Stock Price - MarketBeat Wed, 11 Mar 2026 15
- Free U.S. tryouts offer teens a shot to train with Real Madrid in Spain - Stock Titan Wed, 11 Mar 2026 15
- Is Abbott Laboratories (ABT) Pricing Reflect Its Mixed Share Performance And Growth Prospects? - Yahoo Finance ue, 10 Mar 2026 18
- Citigroup Maintains 'Buy' Rating on ABT, Lowers Price Target to $136.00 | ABT Stock News - GuruFocus Wed, 11 Mar 2026 17
- Abbott Laboratories Offers Long-Term Upside Despite Recent Stumbles (NYSE:ABT) - Seeking Alpha Mon, 09 Mar 2026 13
- Investors - Abbott Fri, 12 Dec 2025 04
- Rep. Gilbert Ray Cisneros, Jr. Sells Off Shares of Abbott Laboratories (NYSE:ABT) - MarketBeat hu, 12 Mar 2026 09
- Is It Time To Revisit Abbott Laboratories (ABT) After Recent Share Price Weakness? - simplywall.st ue, 10 Mar 2026 09
- Abbott (ABT) Stock Sinks As Market Gains: Here's Why - Yahoo Finance Mon, 02 Mar 2026 08
- Abbott Laboratories $ABT Shares Bought by Franklin Resources Inc. - MarketBeat Wed, 11 Mar 2026 11
- Legal & General Group Plc Purchases 864,531 Shares of Abbott Laboratories $ABT - MarketBeat ue, 10 Mar 2026 10
- Abbott Laboratories $ABT Shares Purchased by Schroder Investment Management Group - MarketBeat ue, 10 Mar 2026 10
- Capital International Inc. CA Purchases 144,033 Shares of Abbott Laboratories $ABT - MarketBeat ue, 10 Mar 2026 11
Insider Transactions
| Date | Shares | Value | Url | Text | Insider | Position | Transaction | Start Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|
| 0 | 885 | 102288 | — | Sale at price 115.58 per share. | SALVADORI DANIEL GESUA SIVE | Officer | — | 2026-03-02 00:00:00 | D |
| 1 | 585 | 67614 | — | Sale at price 115.58 per share. | MCCOY JOHN A. JR | Officer | — | 2026-03-02 00:00:00 | D |
| 2 | 613 | 70851 | — | Sale at price 115.58 per share. | MORELAND MARY K | Officer | — | 2026-03-02 00:00:00 | D |
| 3 | 1144 | 132224 | — | Sale at price 115.58 per share. | MORRONE LOUIS H | Officer | — | 2026-03-02 00:00:00 | D |
| 4 | 709 | 81946 | — | Sale at price 115.58 per share. | SHROFF ERIC | Officer | — | 2026-03-02 00:00:00 | D |
| 5 | 263 | 30398 | — | Sale at price 115.58 per share. | CUSHMAN ELIZABETH C | General Counsel | — | 2026-03-02 00:00:00 | D |
| 6 | 27056 | — | — | Stock Award(Grant) at price 0.00 per share. | EARNHARDT LISA D | Officer | — | 2026-02-24 00:00:00 | D |
| 7 | 18502 | — | — | Stock Award(Grant) at price 0.00 per share. | SCOGGINS CHRISTOPHER J | Officer | — | 2026-02-24 00:00:00 | D |
| 8 | 27997 | — | — | Stock Award(Grant) at price 0.00 per share. | BOUDREAU PHILIP P | Chief Financial Officer | — | 2026-02-24 00:00:00 | D |
| 9 | 13951 | — | — | Stock Award(Grant) at price 0.00 per share. | MORELAND MARY K | Officer | — | 2026-02-24 00:00:00 | D |
Financials
| Line Item | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | 11.45M | 5.67M | -5.78M | -330.60K |
| TaxRateForCalcs | 0.23 | 0.21 | 0.14 | 0.17 |
| NormalizedEBITDA | 12.03B | 10.76B | 10.59B | 12.13B |
| TotalUnusualItems | 50.00M | 27.00M | -41.00M | -2.00M |
| TotalUnusualItemsExcludingGoodwill | 50.00M | 27.00M | -41.00M | -2.00M |
| NetIncomeFromContinuingOperationNetMinorityInterest | 6.52B | 13.40B | 5.72B | 6.93B |
| ReconciledDepreciation | 3.12B | 3.22B | 3.24B | 3.27B |
| ReconciledCostOfRevenue | 17.89B | 17.37B | 16.70B | 17.89B |
| EBITDA | 12.07B | 10.79B | 10.54B | 12.13B |
| EBIT | 8.96B | 7.57B | 7.30B | 8.86B |
| NetInterestIncome | -185.00M | -215.00M | -252.00M | -375.00M |
| InterestExpense | 493.00M | 559.00M | 637.00M | 558.00M |
| InterestIncome | 308.00M | 344.00M | 385.00M | 183.00M |
| NormalizedIncome | 6.49B | 13.38B | 5.76B | 6.93B |
| NetIncomeFromContinuingAndDiscontinuedOperation | 6.52B | 13.40B | 5.72B | 6.93B |
| TotalExpenses | 36.27B | 35.12B | 33.63B | 35.29B |
| TotalOperatingIncomeAsReported | 8.05B | 6.83B | 6.48B | 8.36B |
| DilutedAverageShares | 1.75B | 1.75B | 1.75B | 1.76B |
| BasicAverageShares | 1.74B | 1.73B | 1.73B | 1.74B |
| DilutedEPS | 3.72 | 7.64 | 3.26 | 3.91 |
| BasicEPS | 3.76 | 7.74 | 3.30 | 3.99 |
| DilutedNIAvailtoComStockholders | 6.52B | 13.40B | 5.72B | 6.93B |
| NetIncomeCommonStockholders | 6.52B | 13.40B | 5.72B | 6.93B |
| NetIncome | 6.52B | 13.40B | 5.72B | 6.93B |
| NetIncomeIncludingNoncontrollingInterests | 6.52B | 13.40B | 5.72B | 6.93B |
| NetIncomeDiscontinuousOperations | 0.00 | 0.00 | ||
| NetIncomeContinuousOperations | 6.52B | 13.40B | 5.72B | 6.93B |
| TaxProvision | 1.94B | -6.39B | 941.00M | 1.37B |
| PretaxIncome | 8.47B | 7.01B | 6.66B | 8.31B |
| OtherIncomeExpense | 598.00M | 403.00M | 438.00M | 319.00M |
| OtherNonOperatingIncomeExpenses | 548.00M | 376.00M | 479.00M | 321.00M |
| SpecialIncomeCharges | 0.00 | |||
| GainOnSaleOfSecurity | 50.00M | 27.00M | -41.00M | -2.00M |
| NetNonOperatingInterestIncomeExpense | -185.00M | -215.00M | -252.00M | -375.00M |
| InterestExpenseNonOperating | 493.00M | 559.00M | 637.00M | 558.00M |
| InterestIncomeNonOperating | 308.00M | 344.00M | 385.00M | 183.00M |
| OperatingIncome | 8.05B | 6.83B | 6.48B | 8.36B |
| OperatingExpense | 16.96B | 16.42B | 15.66B | 16.15B |
| DepreciationAmortizationDepletionIncomeStatement | 1.68B | 1.88B | 1.97B | 2.01B |
| DepreciationAndAmortizationInIncomeStatement | 1.68B | 1.88B | 1.97B | 2.01B |
| Amortization | 1.68B | 1.88B | 1.97B | 2.01B |
| AmortizationOfIntangiblesIncomeStatement | 1.68B | 1.88B | 1.97B | 2.01B |
| ResearchAndDevelopment | 2.94B | 2.84B | 2.74B | 2.89B |
| SellingGeneralAndAdministration | 12.33B | 11.70B | 10.95B | 11.25B |
| GrossProfit | 25.01B | 23.24B | 22.13B | 24.51B |
| CostOfRevenue | 19.32B | 18.71B | 17.98B | 19.14B |
| TotalRevenue | 44.33B | 41.95B | 40.11B | 43.65B |
| OperatingRevenue | 44.33B | 41.95B | 40.11B | 43.65B |
| Line Item | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| TreasurySharesNumber | 260.20M | 259.77M | 253.81M | 248.72M |
| OrdinarySharesNumber | 1.74B | 1.73B | 1.73B | 1.74B |
| ShareIssued | 2.00B | 1.99B | 1.99B | 1.99B |
| NetDebt | 4.41B | 6.51B | 7.78B | 6.89B |
| TotalDebt | 13.86B | 15.02B | 15.63B | 17.72B |
| TangibleBookValue | 22.57B | 17.91B | 6.11B | 3.43B |
| InvestedCapital | 65.06B | 61.79B | 53.28B | 53.46B |
| WorkingCapital | 9.50B | 9.50B | 8.83B | 9.73B |
| NetTangibleAssets | 22.57B | 17.91B | 6.11B | 3.43B |
| CapitalLeaseObligations | 931.00M | 896.00M | 949.00M | 943.00M |
| CommonStockEquity | 52.13B | 47.66B | 38.60B | 36.69B |
| TotalCapitalization | 62.03B | 60.29B | 52.20B | 51.21B |
| TotalEquityGrossMinorityInterest | 52.77B | 47.90B | 38.83B | 36.91B |
| MinorityInterest | 641.00M | 237.00M | 224.00M | 219.00M |
| StockholdersEquity | 52.13B | 47.66B | 38.60B | 36.69B |
| GainsLossesNotAffectingRetainedEarnings | -6.00B | -7.91B | -7.84B | -8.05B |
| OtherEquityAdjustments | -6.00B | -7.91B | -7.84B | -8.05B |
| TreasuryStock | 17.18B | 16.84B | 15.98B | 15.23B |
| RetainedEarnings | 49.78B | 47.26B | 37.55B | 35.26B |
| CapitalStock | 25.53B | 25.15B | 24.87B | 24.71B |
| CommonStock | 25.53B | 25.15B | 24.87B | 24.71B |
| PreferredStock | 0.00 | 0.00 | 0.00 | 0.00 |
| TotalLiabilitiesNetMinorityInterest | 33.94B | 33.51B | 34.39B | 37.53B |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 17.45B | 19.36B | 20.55B | 22.04B |
| OtherNonCurrentLiabilities | 2.54B | 2.59B | 2.39B | 3.80B |
| EmployeeBenefits | 2.12B | 1.88B | 1.96B | 1.78B |
| NonCurrentPensionAndOtherPostretirementBenefitPlans | 2.12B | 1.88B | 1.96B | 1.78B |
| TradeandOtherPayablesNonCurrent | 1.40B | 857.00M | 1.08B | |
| NonCurrentDeferredLiabilities | 559.00M | 512.00M | 568.00M | 991.00M |
| NonCurrentDeferredTaxesLiabilities | 559.00M | 512.00M | 568.00M | 991.00M |
| LongTermDebtAndCapitalLeaseObligation | 10.83B | 13.52B | 14.55B | 15.46B |
| LongTermCapitalLeaseObligation | 931.00M | 896.00M | 949.00M | 943.00M |
| LongTermDebt | 9.90B | 12.62B | 13.60B | 14.52B |
| CurrentLiabilities | 16.50B | 14.16B | 13.84B | 15.49B |
| CurrentDebtAndCapitalLeaseObligation | 3.03B | 1.50B | 1.08B | 2.25B |
| CurrentDebt | 3.03B | 1.50B | 1.08B | 2.25B |
| PayablesAndAccruedExpenses | 13.46B | 12.66B | 12.76B | 13.24B |
| CurrentAccruedExpenses | 6.88B | 6.22B | 6.37B | 6.76B |
| Payables | 6.59B | 6.43B | 6.39B | 6.47B |
| OtherPayable | 682.00M | 621.00M | 650.00M | 638.00M |
| DividendsPayable | 1.10B | 1.02B | 955.00M | 887.00M |
| TotalTaxPayable | 569.00M | 594.00M | 492.00M | 343.00M |
| IncomeTaxPayable | 569.00M | 594.00M | 492.00M | 343.00M |
| AccountsPayable | 4.24B | 4.20B | 4.29B | 4.61B |
| TotalAssets | 86.71B | 81.41B | 73.21B | 74.44B |
| TotalNonCurrentAssets | 60.72B | 57.76B | 50.54B | 49.21B |
| OtherNonCurrentAssets | 18.42B | 16.46B | 7.10B | 6.03B |
| NonCurrentDeferredAssets | 6.03B | 5.21B | ||
| NonCurrentDeferredTaxesAssets | 6.03B | 5.21B | ||
| InvestmentsAndAdvances | 918.00M | 886.00M | 799.00M | 766.00M |
| OtherInvestments | 321.00M | 333.00M | 244.00M | 208.00M |
| InvestmentinFinancialAssets | 597.00M | 553.00M | 555.00M | 558.00M |
| AvailableForSaleSecurities | 597.00M | 553.00M | 555.00M | 558.00M |
| GoodwillAndOtherIntangibleAssets | 29.56B | 29.75B | 32.49B | 33.25B |
| OtherIntangibleAssets | 5.53B | 6.65B | 8.81B | 10.45B |
| Goodwill | 24.04B | 23.11B | 23.68B | 22.80B |
| NetPPE | 11.82B | 10.66B | 10.15B | 9.16B |
| AccumulatedDepreciation | -13.41B | -12.08B | -11.78B | -11.05B |
| GrossPPE | 25.22B | 22.74B | 21.93B | 20.21B |
| ConstructionInProgress | 2.57B | 2.49B | 2.06B | 1.48B |
| OtherProperties | 17.57B | 15.52B | 15.18B | 14.16B |
| MachineryFurnitureEquipment | 13.53B | |||
| BuildingsAndImprovements | 4.54B | 4.21B | 4.16B | 4.05B |
| LandAndImprovements | 541.00M | 528.00M | 529.00M | 511.00M |
| Properties | 0.00 | 0.00 | 0.00 | 0.00 |
| CurrentAssets | 26.00B | 23.66B | 22.67B | 25.22B |
| PrepaidAssets | 2.35B | |||
| Inventory | 6.49B | 6.19B | 6.57B | 6.17B |
| FinishedGoods | 3.98B | 3.70B | 3.95B | 3.81B |
| WorkInProcess | 904.00M | 840.00M | 807.00M | 680.00M |
| RawMaterials | 1.61B | 1.65B | 1.82B | 1.69B |
| Receivables | 10.57B | 9.49B | 8.82B | 8.88B |
| OtherReceivables | 2.64B | 2.57B | 2.26B | 2.66B |
| AccountsReceivable | 7.93B | 6.92B | 6.57B | 6.22B |
| AllowanceForDoubtfulAccountsReceivable | -490.00M | -439.00M | -444.00M | -500.00M |
| GrossAccountsReceivable | 8.42B | 7.36B | 7.01B | 6.72B |
| CashCashEquivalentsAndShortTermInvestments | 8.94B | 7.97B | 7.28B | 10.17B |
| OtherShortTermInvestments | 417.00M | 351.00M | 383.00M | 288.00M |
| CashAndCashEquivalents | 8.52B | 7.62B | 6.90B | 9.88B |
| Line Item | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| FreeCashFlow | 7.39B | 6.35B | 5.06B | 7.80B |
| RepurchaseOfCapitalStock | -893.00M | -1.29B | -1.23B | -3.79B |
| RepaymentOfDebt | -1.50B | -660.00M | -2.50B | -753.00M |
| IssuanceOfDebt | 5.00M | 223.00M | 2.00M | 7.00M |
| CapitalExpenditure | -2.17B | -2.21B | -2.20B | -1.78B |
| InterestPaidSupplementalData | 545.00M | 604.00M | 662.00M | 563.00M |
| IncomeTaxPaidSupplementalData | 1.93B | 1.72B | 1.48B | 1.86B |
| EndCashPosition | 8.52B | 7.62B | 6.90B | 9.88B |
| BeginningCashPosition | 7.62B | 6.90B | 9.88B | 9.80B |
| EffectOfExchangeRateChanges | 71.00M | -96.00M | -23.00M | -122.00M |
| ChangesInCash | 835.00M | 816.00M | -2.96B | 205.00M |
| FinancingCashFlow | -6.31B | -5.40B | -7.09B | -7.64B |
| CashFlowFromContinuingFinancingActivities | -6.31B | -5.40B | -7.09B | -7.64B |
| NetOtherFinancingCharges | -82.00M | |||
| ProceedsFromStockOptionExercised | 396.00M | 264.00M | 167.00M | 167.00M |
| CashDividendsPaid | -4.12B | -3.84B | -3.56B | -3.31B |
| CommonStockDividendPaid | -4.12B | -3.84B | -3.56B | -3.31B |
| NetCommonStockIssuance | -893.00M | -1.29B | -1.23B | -3.79B |
| CommonStockPayments | -893.00M | -1.29B | -1.23B | -3.79B |
| NetIssuancePaymentsOfDebt | -1.61B | -537.00M | -2.48B | -699.00M |
| NetShortTermDebtIssuance | -115.00M | -100.00M | 21.00M | 47.00M |
| NetLongTermDebtIssuance | -1.50B | -437.00M | -2.50B | -746.00M |
| LongTermDebtPayments | -1.50B | -660.00M | -2.50B | -753.00M |
| LongTermDebtIssuance | 5.00M | 223.00M | 2.00M | 7.00M |
| InvestingCashFlow | -2.42B | -2.34B | -3.13B | -1.74B |
| CashFlowFromContinuingInvestingActivities | -2.42B | -2.34B | -3.13B | -1.74B |
| NetOtherInvestingChanges | 18.00M | 9.00M | 22.00M | 22.00M |
| NetInvestmentPurchaseAndSale | -164.00M | -141.00M | -116.00M | -33.00M |
| SaleOfInvestment | 3.00M | 28.00M | 43.00M | 152.00M |
| PurchaseOfInvestment | -167.00M | -169.00M | -159.00M | -185.00M |
| NetBusinessPurchaseAndSale | -105.00M | 1.00M | -837.00M | 48.00M |
| SaleOfBusiness | 0.00 | 1.00M | 40.00M | 48.00M |
| PurchaseOfBusiness | -105.00M | 0.00 | -877.00M | 0.00 |
| NetPPEPurchaseAndSale | -2.17B | -2.21B | -2.20B | -1.78B |
| PurchaseOfPPE | -2.17B | -2.21B | -2.20B | -1.78B |
| OperatingCashFlow | 9.57B | 8.56B | 7.26B | 9.58B |
| CashFlowFromContinuingOperatingActivities | 9.57B | 8.56B | 7.26B | 9.58B |
| ChangeInWorkingCapital | -803.00M | -9.22B | -2.48B | -1.52B |
| ChangeInOtherWorkingCapital | -585.00M | -383.00M | -908.00M | |
| ChangeInPayablesAndAccruedExpense | 949.00M | -7.67B | -1.34B | 37.00M |
| ChangeInPayable | 949.00M | -7.67B | -1.34B | 37.00M |
| ChangeInAccountPayable | 954.00M | 356.00M | -760.00M | 420.00M |
| ChangeInTaxPayable | -5.00M | -8.03B | -585.00M | -383.00M |
| ChangeInIncomeTaxPayable | -5.00M | -8.03B | -585.00M | -383.00M |
| ChangeInPrepaidAssets | -1.29B | -796.00M | -542.00M | -75.00M |
| ChangeInInventory | 195.00M | -58.00M | -232.00M | -1.41B |
| ChangeInReceivables | -652.00M | -691.00M | -356.00M | -68.00M |
| ChangesInAccountReceivables | -652.00M | -691.00M | -356.00M | -68.00M |
| StockBasedCompensation | 664.00M | 673.00M | 644.00M | 685.00M |
| DepreciationAmortizationDepletion | 3.12B | 3.22B | 3.24B | 3.27B |
| DepreciationAndAmortization | 3.12B | 3.22B | 3.24B | 3.27B |
| AmortizationCashFlow | 1.68B | 1.88B | 1.97B | 2.01B |
| AmortizationOfIntangibles | 1.68B | 1.88B | 1.97B | 2.01B |
| Depreciation | 1.43B | 1.34B | 1.28B | 1.25B |
| OperatingGainsLosses | 65.00M | 482.00M | 126.00M | 215.00M |
| GainLossOnInvestmentSecurities | 65.00M | 482.00M | 126.00M | 215.00M |
| NetIncomeFromContinuingOperations | 6.52B | 13.40B | 5.72B | 6.93B |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for ABT
| Date | User | Broker | Pattern | Type | Position Size | Entry Price | Trade P&L | Status |
|---|